Volume 69, Issue 1, Pages (January 2016)

Slides:

Advertisements

Similar presentations

Volume 68, Issue 6, Pages (December 2015)

Advertisements

Volume 62, Issue 3, Pages (September 2012)

The PSA Era is not Over for Prostate Cancer

A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy William.

Volume 44, Issue 6, Pages (December 2003)

Volume 58, Issue 4, Pages (October 2010)

Volume 69, Issue 5, Pages (May 2016)

Volume 61, Issue 6, Pages (June 2012)

Claude C. Schulman, Jacques Irani, Juan Morote, Jack A

Volume 49, Issue 2, Pages (February 2006)

Volume 70, Issue 4, Pages (October 2016)

Volume 53, Issue 5, Pages (May 2008)

Volume 69, Issue 1, Pages (January 2016)

Volume 69, Issue 5, Pages (May 2016)

Volume 51, Issue 4, Pages (April 2007)

Volume 51, Issue 3, Pages (March 2007)

Volume 65, Issue 5, Pages (May 2014)

Volume 70, Issue 2, Pages (August 2016)

Volume 72, Issue 5, Pages (November 2017)

Who Benefits from Neoadjuvant or Adjuvant Hormone Therapy?

Volume 51, Issue 5, Pages (May 2007)

Volume 52, Issue 4, Pages (October 2007)

Volume 72, Issue 5, Pages (November 2017)

Volume 63, Issue 1, Pages (January 2013)

Supplemental Figure 1: Kaplan-Meier Curves of overall survival based on clinical stage at presentation and treatment modality Kaplan-Meier analyses depicting.

Volume 74, Issue 4, Pages (October 2018)

Volume 71, Issue 1, Pages 1-3 (January 2017)

What is New in Hormone Therapy for Prostate Cancer in 2007?

Volume 61, Issue 4, Pages (April 2012)

Volume 53, Issue 4, Pages (April 2008)

Volume 74, Issue 1, Pages (July 2018)

Volume 67, Issue 3, Pages (March 2015)

Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma Viktor Grünwald, Xun Lin, Daniel Kalanovic,

Volume 71, Issue 5, Pages (May 2017)

Volume 71, Issue 6, Pages (June 2017)

Laurent Boccon-Gibod European Urology Supplements

Volume 53, Issue 4, Pages (April 2008)

Volume 64, Issue 6, Pages (December 2013)

The PSA Era is not Over for Prostate Cancer

Volume 61, Issue 6, Pages (June 2012)

Volume 66, Issue 6, Pages (December 2014)

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Volume 74, Issue 2, Pages (August 2018)

Volume 73, Issue 2, Pages (February 2018)

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial

Volume 70, Issue 2, Pages (August 2016)

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer– specific Mortality: Competition Between Age and Time to Biochemical Failure

Volume 71, Issue 5, Pages (May 2017)

Volume 71, Issue 3, Pages (March 2017)

Bone Health in Patients With Prostate Cancer: Monitoring and Diagnosis

Volume 49, Issue 4, Pages (April 2006)

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 71, Issue 3, Pages (March 2017)

European Urology is “Your” Journal

Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study J.-Y. Feng, S.-F. Huang, W.-Y. Ting, Y.-C.

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

European Urology Oncology

Axel Heidenreich European Urology Supplements

Volume 54, Issue 2, Pages (August 2008)

Volume 54, Issue 1, Pages (July 2008)

Highlighting Unmet Needs: Real Patients, Difficult Choices

Volume 53, Issue 6, Pages (June 2008)

Oncoforum Urology: Prostate Cancer 2008 at a Glance

Axel Heidenreich European Urology Supplements

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer Alex P. Hoyle, Adnan Ali, Nicholas D. James, Adrian Cook, Christopher.

Presentation transcript:

Volume 69, Issue 1, Pages 50-57 (January 2016) Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy William C. Jackson, Matthew J. Schipper, Skyler B. Johnson, Corey Foster, Darren Li, Howard M. Sandler, Ganesh S. Palapattu, Daniel A. Hamstra, Felix Y. Feng European Urology Volume 69, Issue 1, Pages 50-57 (January 2016) DOI: 10.1016/j.eururo.2015.05.009 Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 1 Kaplan-Meier analysis of androgen deprivation therapy (ADT) use and duration. (A) Freedom from biochemical failure (BF), (B) freedom from metastasis, (C) cause-specific survival, and (D) overall survival (OS) for patients stratified by ADT use with radiation therapy. (E) Freedom from BF, (F) freedom from metastasis, (G) cause-specific survival, and (H) OS for patients treated with ADT stratified by ADT duration. ADT=androgen deprivation therapy; BF=biochemical failure; CI=confidence interval; HR=hazard ratio; OS=overall survival; RT=radiation therapy. European Urology 2016 69, 50-57DOI: (10.1016/j.eururo.2015.05.009) Copyright © 2015 European Association of Urology Terms and Conditions